NKGen Biotech (NYSE:NKGN) Shares Up 4%

NKGen Biotech, Inc. (NYSE:NKGN)’s stock price rose 4% during trading on Tuesday . The stock traded as high as $1.32 and last traded at $1.31. Approximately 112,609 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 2,600,783 shares. The stock had previously closed at $1.26.

NKGen Biotech Price Performance

The business has a fifty day moving average price of $1.59.

Institutional Investors Weigh In On NKGen Biotech

An institutional investor recently bought a new position in NKGen Biotech stock. University of Chicago acquired a new stake in shares of NKGen Biotech, Inc. (NYSE:NKGN) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 550,000 shares of the company’s stock, valued at approximately $1,512,000. NKGen Biotech makes up approximately 2.1% of University of Chicago’s holdings, making the stock its 5th largest position. University of Chicago owned approximately 2.51% of NKGen Biotech at the end of the most recent reporting period. Institutional investors and hedge funds own 76.17% of the company’s stock.

About NKGen Biotech

NKGen Biotech, Inc operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials.